Clinical Trials designed by HIV/AIDS Networks supported by NIH's Division of AIDS (DAIDS).
A randomized pilot study of Ruxolitinib in antiretroviral treated HIV infected adults
A5353 is a study for people who are infected with HIV and have never taken HIV medications. Participants will receive Dolutegravir plus Lamivudine for 52 weeks.
This study is being done to see if a medication, sirolimus, can help decrease this immune system activation and inflammation. Sirolimus is a medication approved by the Food and Drug Administration (FDA) to prevent complications after some kidney transplants and stem cell transplants and as a treatment for certain kinds of cancers in HIV-infected patients.
This study is for people who are infected with both HIV-1(the virus that causes AIDS) and HCV (a virus that causes hepatitis; an inflammation of the liver, specifically genotype 1 which is one of the main types of hepatitis C). People participating in the study must be HCV treatment naïve (individuals who have never taken Hepatitis C medications). Treatment for the HCV virus usually consists of a combination of drugs including interferon. New drugs are being developed to treat people who are infected with HCV. These drugs are being tested as a part of drug regimens that do not contain the drug interferon. These regimens could be useful in treating people who are infected with both HCV and HIV because these people often do not respond well to interferon (it does not treat their HCV effectively and they may have complications from taking the drug, such as depression and changes in their blood counts).
This is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC) and Dolutegravir 9DTG) to the current antiretroviral therapy (ART) of HIV-infected individuals with undetectable HIV-1 RNA, who have mild to moderate neurocognitive impairment, with a primary outcome of improvement in neurocognitive performance.
This study will assess the usefulness of a cholesterol lowering medication called Pitavastatin for preventing heart disease among HIV infected adults between the ages of 40 to 75 years of age.
This study is an open-label, two cohort study, in which 44 acutely HCV infected HIV-1 positive subjects will be enrolled and administered oral sofosbuvir (SOF) in combination with weight based ribavirin (RBV)
This study will evaluate the safety and efficacy of a single dose administration of romidepsin (RMD).
This study will help to understand the impact of successful (sustained viral response) or unsuccessful Hepatitis C virus treatment on a persons health over many years.